IRIS
GALETTI, Maricla
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.414
AS - Asia 4.508
EU - Europa 3.816
SA - Sud America 589
AF - Africa 242
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 14.579
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.298
SG - Singapore 1.457
CN - Cina 1.237
IT - Italia 1.134
VN - Vietnam 831
FI - Finlandia 548
IE - Irlanda 482
BR - Brasile 446
SE - Svezia 434
DE - Germania 331
HK - Hong Kong 302
FR - Francia 182
BD - Bangladesh 166
UA - Ucraina 141
ZA - Sudafrica 135
NL - Olanda 124
GB - Regno Unito 115
IN - India 113
TR - Turchia 102
RU - Federazione Russa 90
CA - Canada 70
AR - Argentina 60
AT - Austria 51
CI - Costa d'Avorio 49
BE - Belgio 40
KR - Corea 40
PL - Polonia 36
ES - Italia 29
JP - Giappone 29
MX - Messico 28
ID - Indonesia 27
IQ - Iraq 27
CO - Colombia 21
PK - Pakistan 21
EC - Ecuador 20
PH - Filippine 19
TH - Thailandia 17
SA - Arabia Saudita 15
MA - Marocco 14
CZ - Repubblica Ceca 13
UZ - Uzbekistan 13
VE - Venezuela 13
LT - Lituania 11
EG - Egitto 9
PY - Paraguay 9
TN - Tunisia 9
AL - Albania 8
KE - Kenya 8
MY - Malesia 8
CH - Svizzera 7
HU - Ungheria 7
IR - Iran 7
JO - Giordania 7
SY - Repubblica araba siriana 7
AZ - Azerbaigian 6
BO - Bolivia 6
CL - Cile 6
KZ - Kazakistan 6
NP - Nepal 6
TW - Taiwan 6
AU - Australia 5
KG - Kirghizistan 5
LB - Libano 5
PE - Perù 5
DO - Repubblica Dominicana 4
DZ - Algeria 4
ET - Etiopia 4
OM - Oman 4
PA - Panama 4
PS - Palestinian Territory 4
PT - Portogallo 4
RO - Romania 4
AE - Emirati Arabi Uniti 3
GE - Georgia 3
GR - Grecia 3
JM - Giamaica 3
LU - Lussemburgo 3
LV - Lettonia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
UY - Uruguay 3
AM - Armenia 2
BH - Bahrain 2
BY - Bielorussia 2
CY - Cipro 2
EE - Estonia 2
GA - Gabon 2
HN - Honduras 2
HR - Croazia 2
QA - Qatar 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TJ - Tagikistan 2
AD - Andorra 1
BB - Barbados 1
BF - Burkina Faso 1
BW - Botswana 1
CR - Costa Rica 1
DK - Danimarca 1
Totale 14.564
Salva come PNG Salva come JPEG
Città #
Singapore 763
Ashburn 618
Dallas 589
San Jose 482
Dublin 481
Chandler 458
Parma 384
Santa Clara 322
Hong Kong 282
Beijing 278
Ann Arbor 273
Ho Chi Minh City 258
Hanoi 175
Jacksonville 160
Boardman 155
Dearborn 153
New York 146
Los Angeles 134
Johannesburg 128
Shanghai 113
Munich 104
Nanjing 97
Hefei 95
Chicago 88
Lauterbourg 81
Council Bluffs 74
Princeton 74
Izmir 72
Milan 71
Bremen 56
São Paulo 54
San Mateo 51
Abidjan 49
Helsinki 47
Wilmington 47
Buffalo 44
Vienna 44
Bologna 42
Moscow 42
Haiphong 40
Rome 39
Shenyang 39
Nanchang 36
Da Nang 35
Modena 33
Toronto 32
Columbus 31
Kunming 30
Tianjin 30
Des Moines 29
The Dalles 29
Warsaw 29
Marseille 28
Jinan 27
Frankfurt am Main 26
Seattle 26
Seoul 25
London 24
Brussels 23
Houston 23
Reggio Emilia 23
Stockholm 23
Turku 23
Jakarta 22
Phoenix 22
Tokyo 22
Denver 21
Hebei 21
Guangzhou 20
Nuremberg 18
Atlanta 17
Brooklyn 17
Montreal 17
Chennai 16
Boston 15
Brasília 15
Poplar 15
Redmond 15
Verona 15
Amsterdam 14
Changsha 14
Jiaxing 14
Manchester 14
Orem 14
Rio de Janeiro 14
Norwalk 13
Pune 13
Tashkent 13
Woodbridge 13
Zhengzhou 13
Bến Tre 12
Düsseldorf 12
Leawood 12
Wayne 12
Bari 11
Brescia 11
Can Tho 11
Florence 11
Dong Ket 10
Naples 10
Totale 8.836
Salva come PNG Salva come JPEG
Nome #
A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC 283
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 264
Highly-defined bioprinting of long-term vascularized scaffolds with Bio-Trap: Complex geometry functionalization and process parameters with computer aided tissue engineering 264
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 251
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 247
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 244
Subchronic exposure to titanium dioxide nanoparticles modifies cardiac structure and performance in spontaneously hypertensive rats 231
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 218
Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines. 215
Three-Dimensional Bioprinting of Organoid-Based Scaffolds (OBST) for Long-Term Nanoparticle Toxicology Investigation 213
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 211
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 204
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 203
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 201
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 201
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 200
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 197
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 196
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 193
Autophagy and apoptosis: studies on the effects of bisthiosemicarbazone copper(II) complexes on p53 and p53-null tumour cell lines 193
Synthesis of Fe3O4 superparamagnetic nanoparticles and anchoring via ‘click’ chemistry to SiC/SiO2 nanowires for radiofrequency magnetic field hyperthermia 192
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 191
A three-fold novel nanosystem made by SiC/SiO2 core/shell nanowires functionalized with magnetic nanoparticles and substituted porphyrin for nanomedicine applications 190
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 190
A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models 186
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 185
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 180
Nanoparticles exposure: In-vitro and in-vivo investigation to evaluate cardiovascu1ar risk factors in normal and failing cardiac tissue [Esposizione a nanoparticelle: Studi in-vitro ed in-vivo per valutare i fattori di rischio cardiovascolari in cuori normali e patologici] 180
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 178
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 177
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 177
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 175
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 174
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 173
Sirolimus plus prednisone for Erdheim-Chester disease: An open-label trial 173
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 171
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 171
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 170
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 170
Association of serum C3 concentration and histologic signs of thrombotic microangiopathy with outcomes among patients with ANCA-associated renal vasculitis 169
Titanium dioxide aggregating nanoparticles induce autophagy and under-expression of microRNA 21 and 30a in A549 cell line: A comparative study with cobalt(II, III) oxide nanoparticles 166
SiC/SiO2/M-NP core/shell nanowires functionalized with fluorinated porphyrins 165
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 163
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 161
Critical Issues in Assessing Occupational Exposure to Diesel Dust Exhaust 161
Cytocompatibility and Cellular Internalization Mechanisms of SiC/SiO2 Nanowires 161
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 160
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 158
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 158
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 158
Cardiac kinematic parameters computed from video of in situ beating heart 158
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 157
Interaction between occupational radon exposure and tobacco smoke: a systematic review 155
Gefitinib metabolism by CYP1A1 affects biological responses in NSCLC cell lines. 155
SiO2/SiC core-shell nanowires for nanomedicine applications 149
Synergistic activity of letrozole and sorafenib on breast cancer cells 147
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 147
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 147
New MDR1 inhibitors for overcoming multidrug resistance 146
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 145
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 144
Cytocompatible 3C-SiC/SiO2 core shell nanowires for bimodal cancer therapy 143
SiO2/SiC core-shell nanowires for nanomedicine applications 143
Glomerular autoimmune multicomponents of human lupus nephritis in vivo: α-enolase and annexin AI 142
Anti-proliferative effect of induced Fhit expression in non small cell lung cancer cell line (Calu-1) 142
Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review 140
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 139
Study and characterization of a new magnetic nanocomposite system for nanomedicine 137
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 130
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 128
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 126
Correction to: Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer (Cancers, (2020), 12, 3, (666), 10.3390/cancers12030666) 124
Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer 121
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 119
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones 117
Chapter 9 - Innovation in nanomedicine and engineered nanomaterials for therapeutic purposes 116
Role of cell gefitinib metabolism in the response of NSCLC cell lines to gefitinib. 114
In vitro characterization of efflux and metabolism of gefitinib 108
T-DM1: a new therapeutic approach in HER-2 overexpressing NSCLC cell lines 105
Espressione Inducibile del gene FHIT in cellule di carcinoma polmonare 104
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines 104
The maintenance of gefitinib inhibits migration and epithelial-mesenchimal transition of Non-small cell lung cancer cell lines that have become resistant after prolonged gefitinib treatment 104
Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): Planted antigens 99
Optimizing EGFR inhibitor treatment in non small cell lung cancer 96
The inducible coexpression of p53 and FHIT has a synergistic anti-proliferative effect in calu-1 lung cancer cell line 95
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 92
Effect of inducile FHIT and p53 expression in Calu-1 lung cancer cell line. 92
Espressione inducibile di Fhit e p53 in cellule di carcinoma polmonare non a piccole cellule 91
Studio dell’espressione del gene FHIT in cellule di carcinoma polmonare 89
New irreversible inhibitors of EGFR tyrosine kinase activity to circumvent iressa resistance 89
Effect of inducible Fhit and p53 expression in Calu-1 lung cancer cell line 79
Effects of sorafenib on energy metabolism in breast cancer cells: Role of AMPK-mTORC1 signaling 40
null 31
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC 16
Totale 14.777
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.542
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.542
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202141 0 0 0 0 0 0 0 0 0 0 0 41
2021/2022427 30 19 22 29 15 9 56 36 23 24 24 140
2022/20231.835 151 220 119 107 171 204 18 137 586 17 78 27
2023/2024969 44 75 48 37 67 174 77 87 39 59 105 157
2024/20252.729 128 126 161 205 248 304 182 131 347 220 241 436
2025/20266.047 477 486 846 609 777 322 662 166 789 454 299 160
Totale 14.777